1-(3-Methyl-1-Phenyl-5-Pyrazolyl)piperazine CAS 401566-79-8 Purity >99.5% (HPLC) Teneligliptin HBr Intermediate Factory

Name: 1-(3-Methyl-1-Phenyl-5-Pyrazolyl)piperazine  CAS: 401566-79-8 Purity: >99.5% (by HPLC)  Assay: >99.5% (On Dried Basis) Appearance: Off-White to Light Brown Solid Intermediate of  Teneligliptin HBr (CAS: 906093-29-6) High Quality, Commercial Production E-Mail: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureSupply Teneligliptin Hydrobromide Related Intermediates With High Purity Teneligliptin Hydrobromide CAS 906093-29-6 1-(3-Methyl-1-Phenyl-5-Pyrazolyl)piperazine CAS 401566-79-8 Teneligliptin Hydrobromide Intermediate CAS 401564-36-1
Item Specifications
Appearance Off-White to Light Brown Solid
Identification IR; HPLC RT
Loss on Drying <0.50%
Purity / Analysis Method >99.5% (by HPLC)
Assay >99.5% (On Dried Basis)  
Single Impurity <0.50%
Test Standard Enterprise Standard
Usage Intermediates of Teneligliptin HBr (CAS: 906093-29-6)

Description:

Specifications:

Package & Storage:

Chemical Name 1-(3-Methyl-1-Phenyl-5-Pyrazolyl)piperazine
Synonyms 1-(3-Methyl-1-Phenyl-1H-Pyrazol-5-yl)piperazine; Teneligliptin Impurity A 
CAS Number 401566-79-8
CAT Number RF-PI1817
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C14H18N4
Molecular Weight 242.32
Density  1.19
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

1-(3-Methyl-1-Phenyl-5-Pyrazolyl)piperazine (CAS: 401566-79-8) is an intermediate used to prepare Teneligliptin HBr (CAS: 906093-29-6). Teneligliptin HBr is a DPP-4 inhibitor which was approved in Japan in 2012 for the treatment of type II diabetes. Teneligliptin HBr was discovered and developed by Mitsubishi Tanabe Pharma under the trade name Tenelia®. Similar to other marketed DPP-4 inhibitors, Teneligliptin was well tolerated in all studies and QD dosing produced a long-lasting inhibitory action against DPP-4 and an increase in active GLP-1 levels, with very low rates of renal excretion.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours